Format

Send to

Choose Destination
Prostate. 2020 Feb;80(2):113-132. doi: 10.1002/pros.23934. Epub 2019 Dec 11.

Prostate cancer research: The next generation; report from the 2019 Coffey-Holden Prostate Cancer Academy Meeting.

Author information

1
Science Department, Prostate Cancer Foundation, Santa Monica, California.
2
Division of Clinical Studies, Institute of Cancer Research, London, UK.
3
Department of Medicine, The Royal Marsden NHS Foundation Trust, London, UK.
4
Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts.
5
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
6
The Broad Institute of MIT and Harvard University, Cambridge, Massachusetts.
7
National Cancer Institute, Center for Cancer Research, National Institutes of Health, Bethesda, Maryland.
8
Department of Medicine, Baylor College of Medicine, Houston, Texas.
9
Division of Immunology, Department of Pathology, The Johns Hopkins School of Medicine, Baltimore, Maryland.
10
Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
11
Department of Epidemiology & Biostatistics, University of California San Francisco, San Francisco, California.
12
Department of Pathology, University of California Los Angeles, Los Angeles, California.
13
Department of Urology, University of California Los Angeles, Los Angeles, California.
14
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins School of Medicine, Baltimore, Maryland.
15
Department of Urology, The James Buchanan Brady Urological Institute, Baltimore, Maryland.
16
Department of Pharmacology and Molecular Sciences, The Johns Hopkins School of Medicine, Baltimore, Maryland.

Abstract

INTRODUCTION:

The 2019 Coffey-Holden Prostate Cancer Academy (CHPCA) Meeting, "Prostate Cancer Research: The Next Generation," was held 20 to 23 June, 2019, in Los Angeles, California.

METHODS:

The CHPCA Meeting is an annual conference held by the Prostate Cancer Foundation, that is uniquely structured to stimulate intense discussion surrounding topics most critical to accelerating prostate cancer research and the discovery of new life-extending treatments for patients. The 7th Annual CHPCA Meeting was attended by 86 investigators and concentrated on many of the most promising new treatment opportunities and next-generation research technologies.

RESULTS:

The topics of focus at the meeting included: new treatment strategies and novel agents for targeted therapies and precision medicine, new treatment strategies that may synergize with checkpoint immunotherapy, next-generation technologies that visualize tumor microenvironment (TME) and molecular pathology in situ, multi-omics and tumor heterogeneity using single cells, 3D and TME models, and the role of extracellular vesicles in cancer and their potential as biomarkers.

DISCUSSION:

This meeting report provides a comprehensive summary of the talks and discussions held at the 2019 CHPCA Meeting, for the purpose of globally disseminating this knowledge and ultimately accelerating new treatments and diagnostics for patients with prostate cancer.

KEYWORDS:

artificial intelligence; cancer immunotherapy; precision medicine; therapeutics; tumor genomics

PMID:
31825540
DOI:
10.1002/pros.23934

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center